[Exavir: Implementation and evaluation of experimental pharmacology skills acquisition by pharmacy students]. / Exavir : mise en place et évaluation de l'acquisition de compétences en pharmacologie expérimentale par des étudiants en pharmacie.

With the evolution of European and French regulations on animal experimentation in higher education, taking greater account of animal welfare, the University of Angers has developed a virtual animal experimentation software named Exavir. Used for practical work (PW) in physiology, pharmacology and toxicology in the Health, Sciences, and engineering curricula, Exavir can be used to simulate various experiments for teaching purposes, in vivo or ex vivo. Thanks to an original approach integrating serious games with different scenarios, students gain autonomy and become directly involved in their learning. In addition, Exavir's collaborative and participative development approach fosters inter-university partnerships and the emergence of innovative teaching methods. A hybrid pilot study carried out on a sample of 22 students in the Pharmacy Department of the Faculty of Health showed that Exavir improved students' acquisition of teaching skills in both physiology and pharmacology, compared with practical work only based on animal organs. These encouraging results demonstrate for the first time the pedagogical advantages of Exavir and confirm the interest in developing such a platform. In this context, it appears that Exavir also opens up the possibility of adapting the practical work offered within universities, and thus responding to the changing ethical issues of the coming decades.

Review of the pharmacological properties of marine macroalgae used in the treatment of diabetes mellitus in Indonesia.

Indonesia is the largest archipelagic country in the world, with 70% of its territory covered by oceans that are rich in various types of biological resources. Indonesia's biodiversity has made it possible to develop natural medicine. Marine algae have enormous potential, but the types of marine algae used still need to be more varied. Research on the pharmacology of marine macroalgae has been conducted in Indonesia, but studies on such topic related to diabetes mellitus (DM) still need to be completed. This study provides a comprehensive dataset of pharmacological anti-diabetic potential of marine macroalgae used for managing DM and reports on preclinical trials that provide pharmacological evidence. Data on the Indonesian marine macroalgae used to lower blood glucose were obtained from online sources. The bioactive chemicals of marine macroalgae have been found efficient at blocking several diabetes enzymes in in-vivo and in-vitro studies, and such chemicals have anti-inflammatory, anti-obesity, antioxidant, and other therapeutic benefits. The Google Scholar was used to search for the pharmacological literature with the keywords marine AND macroalgae AND diabetes AND Indonesia. Pharmacological research on the anti-diabetic activity of marine macroalgae has been carried out on five major Indonesian islands, including Sumatra, Kalimantan, Java, Sulawesi, and Papua, which encompassed 12 provinces: Southwest Papua, South Sulawesi, West Kalimantan, Riau Archipelago, Banten, West Java, North Sulawesi, East Java, Yogyakarta, Maluku, Jakarta, and Bengkulu. Articles on preclinical tests (in vitro and in vivo) were also used for the phytochemical problem section. The results briefly describe which class of algae has been widely used in Indonesia as an anti-diabetic. The findings of this research can be utilized to help find DM treatment drugs based on natural resources from marine macroalgae.

[A pharmacologic approach to treatment of Mycobacterium abscessus pulmonary disease]. / Analyse pharmacologique du traitement des pneumopathies à Mycobacterium abscessus.

Mycobacterium abscessus is a fast-growing non-tuberculous mycobacteria complex causing pulmonary infections, comprising the subspecies abscessus, massiliense and bolletii. Differences are based predominantly on natural inducible macrolide resistance, active in most Mycobacterium abscessus spp abscessus species and in Mycobacterium abscessus spp bolletii but inactive in Mycobacterium abscessus spp massiliense. Therapy consists in long-term treatment, combining multiple antibiotics. Prognosis is poor, as only 40% of patients experience cure. Pharmacodynamic and pharmacokinetic data on M. abscessus have recently been published, showing that therapy ineffectiveness might be explained by intrinsic bacterial resistance (macrolides…) and by the unfavorable pharmacokinetics of the recommended antibiotics. Other molecules and inhaled antibiotics are promising.

Structure-activity relationship of three new piperazine derivates with anxiolytic-like and antidepressant-like effects.

Anxiety and depression are common mental disorders affecting millions of people worldwide. Unsatisfactory clinical outcomes with the use of the available pharmacological interventions among some patients demand newer drugs with proven efficacy, safety, and tolerability profile. In this study, the LQFM211, LQFM213, and LQFM214 were designed from the piperazine scaffold and administered orally in mice. These mice were later evaluated in the open field, elevated plus maze, and forced swimming tests to assess the exploratory, anxiolytic, and antidepressant-like activities, respectively. The mechanism of action of these new derivatives was evaluated using flumazenil (benzodiazepine antagonist) and WAY100635 (5-HT1A receptor antagonist). Unlike LQFM214, the LQFM211 and LQFM213 elicited anxiolytic and antidepressant-like effects. The blockade of the effect of LQFM213 by WAY100635 suggests the involvement of the serotonergic pathway.

[Pharmacology of cannabidiol: Red flags, consequences and risks in humans]. / Pharmacologie du cannabidiol : points de vigilance, conséquences et risques chez l'homme.

Scientific knowledge about cannabidiol (CBD) demonstrates that CBD is a substance that is not pharmacologically inert. If it does not act efficiently on cannabinoid receptors (those where tetrahydrocannabidol [THC] is fixed), it acts on brain receptors, especially on dopamine and serotonin receptors, making it a psychoactive product in its own right. Its consumption can thus have psychoactive effects, such as sedation and drowsiness for example. In humans, interactions between CBD and drugs such as anti-epileptics, anticoagulants, immunosuppressants or methadone, have been highlighted. Therefore, the drug treatment of patients with chronic diseases may be impacted because of the unknown interaction with CBD. In addition, a recent experimental study has shown that the use of CBD by vaping (e-cigarette) generated by pyrolysis, products containing THC; it could result in possible negative health consequences for the user in terms of clinical effects and/or collateral effects (including on driving). Finally, therapeutic claims (outside of authorized drugs) that are purely speculative at this stage may divert users from proven management (stopping their drug treatment in favor of CBD or "self-medication"). All these data underline the importance of implementing measures related to the accessibility of CBD in order to avoid public health consequences and to better protect the users.

[Pharmacological and multimodal care of the adult patient with psychiatric presentation in the emergency department]. / Soins pharmacologiques du patient adulte à présentation psychiatrique dans les structures d'urgence.

The pharmacological management of patients with psychiatric presentations, on prescription, and by nurses in emergency medicine structures is based on knowledge of a limited number of molecules and their methods of administration. This is accompanied by a relational approach and techniques to ensure the safety of the teams in the case of an agitated or very resistant patient.

[Treatments for depression in consultation-liaison psychiatry: From theory to practice]. / Les traitements de la dépression en psychiatrie de liaison : de la théorie à la pratique.

Treatments for depression include an adapted lifestyle, physical activity, psychotherapies, antidepressant and mood stabilizing drugs, neuromodulation, chronotherapy, spa treatments. Drug treatments used for major depressive episode are antidepressants and mood stabilizers. For a mild episode, psychotherapy is indicated. It should be combined with an antidepressant (serotonin reuptake inhibitor) for moderate and severe episodes. Suicide risk assessment is essential throughout the depressive episode. It is recommended to monitor at the start of antidepressant treatment for suicidal behavior, a change in mood suggesting an underlying bipolar disorder. The effectiveness of the treatment is evaluated after 4 to 8 weeks. The total duration of antidepressant treatment for an EDC is between 6 months and 1 year after remission, in order to prevent relapses. The use of liaison psychiatry, a real healthcare system within the general hospital, is strongly recommended for better screening and treatment of depression, thus reducing the length of hospital stays, improving the prognosis of depression. The aim of this article is to provide clinicians with a summary of validated data on the efficacy/tolerance of treatment for depression, and to suggest practical action to be taken on the main daily clinical situations: treating comorbid conditions, taking into account interactions drugs, manage the serotonin syndrome, lead to withdrawal from antidepressants, manage treatment in the elderly.

COVID-19 pathophysiology and pharmacology: what do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials.

Coronavirus disease 2019 (COVID-19) has resulted in the death of over 18 000 Canadians and has impacted the lives of all Canadians. Many Canadian research groups have expanded their research programs to include COVID-19. Over the past year, our knowledge of this novel disease has grown and has led to the initiation of a number of clinical vaccine and drug trials for the prevention and treatment of COVID-19. Here, we review SARS-CoV-2 (the coronavirus that causes COVID-19) and the natural history of COVID-19, including a timeline of disease progression after SARS-CoV-2 exposure. We also review the pathophysiological effects of COVID-19 on the organ systems that have been implicated in the disease, including the lungs, upper respiratory tract, immune system, central nervous system, cardiovascular system, gastrointestinal organs, the liver, and the kidneys. Then we review general therapeutics strategies that are being applied and investigated for the prevention or treatment of COVID-19, including vaccines, antivirals, immune system enhancers, pulmonary supportive agents, immunosuppressants and (or) anti-inflammatories, and cardiovascular system regulators. Finally, we provide an overview of all current Health Canada authorized clinical drug and vaccine trials for the prevention or treatment of COVID-19.

[Learning through play in the hospital: reality or illusion?] / Apprendre en s'amusant à l'hôpital : réalité ou illusion ?

Healthcare professionals have an obligation to maintain their knowledge at the highest level throughout their careers. To this end, the hospital team of a pharmacy for indoor use has developed an original and entertaining training course, mainly intended for nurses, on the subject of analgesics.

[Literature review on phyto-therapeutics for the treatment of bovine mastitis]. / Literaturübersicht zum Thema ­Phytotherapie zur Behandlung von ­Mastitis beim Rind.

INTRODUCTION: Literature review on phyto-therapeutics for the treatment of bovine mastitis.

INTRODUCTION: Afin de trouver une alternative aux traitements antibiotiques conventionnels des mammites bovines, une recherche bibliographique a été menée en 2015 sur les agents phytothérapeutiques qui ont été étudiés in vitro et utilisés in vivo (sur des patients) dans le monde entier. Une recherche bibliographique est l'une des premières étapes du développement d'un agent phytothérapeutique peroral contre les mammites bovines en utilisant la méthode de «pharmacologie inverse¼. Des phytothérapies citées dans le monde entier dans tous les types d'administration ont été compilées et comptées. Un total de 935 citations pertinentes différentes ont été trouvées dans 195 publications, qui ont été séparées et comptées en fonction de leur type d'appli­cation et de l'espèce cible. La liste de toutes les plantes et les citations peuvent être téléchargés à partir de http://vets.ch/desktop/liste-des-plantes_fuchs_def_sat.pdf . On a répertorié dans la présente étude 106 plantes pour l'application perorale, 45 plantes pour l'application intra mammaire et 24 huiles essentielles (perorale, intra mammaire ou topique) pour le traitement des mammites bovines. La condition préalable à cette sélection était que les plantes soient mentionnées dans la littérature comme agent thérapeutique. En outre, il a été pris en compte si des études in vitro ou in vivo avaient déjà été menées. D'une part, cette liste devrait servir de preuve de l'utilisation traditionnelle des plantes dans le traitement des mammites bovines et, d'autre part, constituer une base pour de nouvelles recherches.

Exposure of Agrobacterium tumefaciens to agroinfiltration medium demonstrates cellular remodelling and may promote enhanced adaptability for molecular pharming.

Agroinfiltration is used to treat plants with modified strains of Agrobacterium tumefaciens for the purpose of transient in planta expression of genes transferred from the bacterium. These genes encode valuable recombinant proteins for therapeutic or industrial applications. Treatment of large quantities of plants for industrial-scale protein production exposes bacteria (harboring genes of interest) to agroinfiltration medium that is devoid of nutrients and carbon sources for prolonged periods of time (possibly upwards of 24 h). Such conditions may negatively influence bacterial viability, infectivity of plant cells, and target protein production. Here, we explored the role of timing in bacterial culture preparation for agroinfiltration using mass spectrometry-based proteomics to define changes in cellular processes. We observed distinct profiles associated with bacterial treatment conditions and exposure timing, including significant changes in proteins involved in pathogenesis, motility, and nutrient acquisition systems as the bacteria adapt to the new environment. These data suggest a progression towards increased cellular remodelling over time. In addition, we described changes in growth- and environment-specific processes over time, underscoring the interconnectivity of pathogenesis and chemotaxis-associated proteins with transport and metabolism. Overall, our results have important implications for the production of transiently expressed target protein products, as prolonged exposure to agroinfiltration medium suggests remodelling of the bacterial proteins towards enhanced infection of plant cells.

[Update on beta blockers in 2020]. / Mise au point sur les bêtabloquants en 2020.

Beta-blockers (BB) are an heterogenous set of molecules actively blocking ß adrenergic receptors. Their pharmacological properties depend on their various effects on the adrenergic signalling. Although they are no longer a first-choice treatment in hypertensive patients, they remain a cornerstone of pharmacological strategy in several cardiovascular diseases such as stable angina, heart failure, arrythmia and aortic related connective diseases. Beyond their usual non cardiovascular indications such as migraine, hepatic cirrhosis, glaucoma, infantile hemangioma, and hyperthyroidism, new therapeutic fields are under scrutiny. Potential BB therapeutic repurposing is being investigated in COPD and cancer patients. This narrative review first encompasses the basic pharmacological knowledge that may be useful for the clinician. Then it will detail BB main indications before exploring new therapeutic fields.

[Physiological and Psychological Data influencing Pregnant Women Smoking Behavior - CNGOF-SFT Expert Report and Guidelines for Smoking Management during Pregnancy]. / Données physiologiques et psychologiques influençant le comportement tabagique de la femme enceinte ­ Rapport d'experts et recommandations CNGOF-SFT sur la prise en charge du tabagisme en cours de grossesse.

Nicotine is the main addictive substance in tobacco and its addictive effects mainly involve dopamine. Nicotine is mainly metabolized (C-oxidation) in the liver to cotinine by the cytochrome P450 enzyme system. Nicotine half-life is short being about 2hours. Nicotine metabolism appears to be increased during pregnancy, mainly due to an increased cytochrome activity and maternal cardiac output. Thus, the smoking behavior of the pregnant woman is subsequently modified with an increase in withdrawal syndromes and an increased desire to smoke. These pharmacological elements should be taken into account when prescribing nicotine replacement therapy. Regarding the markers of tobacco intoxication, there is a good correlation between the importance of smoking and the measurement of expired air carbon monoxide. Although there is no evidence of decreased obstetrical complications related to its use, it is simple and non-invasive and therefore may be useful in routine practice. It gives an instantaneous value of tobacco intoxication, and represents a starting point for dialogue and management and can help to highlight the reality of withdrawal. Regarding the evaluation of tobacco addiction, the most commonly used questionnaires are the Fagerström tests (FTCD, HSI…), which are well correlated with cotinine concentration. However, there is insufficient evidence of their usefulness in reducing tobacco consumption during pregnancy to recommend them in current practice. DSM-V diagnostic criteria for addiction should be known as they can also be used to characterize the intensity of this addiction.

[PET imaging for better understanding of normal and pathological neurotransmission]. / L'imagerie TEP pour une meilleure compréhension de la neurotransmission normale et pathologique.

Positron emission tomography imaging is still an expanding field of preclinical and clinical investigations exploring the brain and its normal and pathological functions. In addition to technological improvements in PET scanners, the availability of suitable radiotracers for unexplored pharmacological targets is a key factor in this expansion. Many radiotracers (or radiopharmaceuticals, when administered to humans) have been developed by multidisciplinary teams to visualize and quantify a growing numbers of brain receptors, transporters, enzymes and other targets. The development of new PET radiotracers still represents an exciting challenge, given the large number of neurochemical functions that remain to be explored. In this article, we review the development context of the first preclinical radiotracers and their passage to humans. The main current contributions of PET radiotracers are described in terms of imaging neuronal metabolism, quantification of receptors and transporters, neurodegenerative and neuroinflammatory imaging. The different approaches to functional imaging of neurotransmission are also discussed. Finally, the contributions of PET imaging to the research and development of new brain drugs are described.

TITLE: L'imagerie TEP pour une meilleure compréhension de la neurotransmission normale et pathologique. ABSTRACT: La neuroimagerie des récepteurs cérébraux a commencé au début des années 1980. Aujourd'hui, quelque quarante ans plus tard, l'imagerie par tomographie d'émission de positons (TEP) est toujours un domaine en expansion dans les études précliniques et cliniques cherchant à explorer le cerveau et son fonctionnement normal et pathologique. Outre les améliorations apportées aux caméras TEP et à l'analyse d'images, la disponibilité de radiotraceurs est un facteur déterminant de cette expansion. De nombreux radiotraceurs (ou radiopharmaceutiques, lorsque injectés chez l'Homme) ont été mis au point par des équipes pluridisciplinaires pour visualiser et quantifier un nombre croissant de récepteurs, transporteurs, enzymes et autres cibles moléculaires du cerveau. Le développement de nouveaux radiotraceurs TEP représente un défi passionnant, du fait du grand nombre de cibles et de fonctions neurochimiques qui restent encore à explorer. Dans cet article, nous resituons le contexte de développement des premiers radiotraceurs précliniques et leur passage à l'Homme. Les principales contributions actuelles des radiotraceurs TEP sont décrites en termes d'imagerie du métabolisme neuronal, de quantification des récepteurs et des transporteurs, d'imagerie neurodégénérative et neuroinflammatoire. Les différentes approches d'imagerie fonctionnelle de la neurotransmission sont également abordées. Enfin, les apports de l'imagerie TEP à la recherche et au développement de nouveaux médicaments du cerveau sont décrits.

Erasing the Personal Baseline: Graphing Responders to Psychiatric Drug Maintenance Therapy.

Since the 1950s, the practice of psychiatric drug maintenance therapy has been supported by graphics. Lacking physical markers to identify "responders" to long-term drugs, psychiatrists have used graphics to make the outcomes of their interventions visible. This article identifies changes in the graphical representation of drug responders in psychiatric journals between the mid-1950s and the mid-1990s. It argues that before 1970, psychiatrists assessed patients' responses in relation to their personal baselines or symptom trajectories. After 1970, clinical trials made it possible to see responders through a statistical lens, as a homogeneous population, decontextualized from its past and having a future consisting of two possible states: relapse or remission. Abstracted from their life's context, responders became the desired outcome of prescribing protocols that could be applied anywhere. Psychiatry's graphical language supported an authoritative view of mental health as something to be optimized and maintained with prescription drugs.

[Improve the benefit/risk balance of methadone by respecting its pharmacological specificities]. / Améliorer la balance bénéfices/risques de la méthadone en respectant ses spécificités pharmacologiques.

Recent data on methadone from 2008 to 2017 by the French addictovigilance network warms on the increase of methadone use, its diversion, its increase of overdose risk factors (opioids associated, occasional use) and deaths. Whereas methadone is an essential drug for opioid addiction, its use remains complex because of its pharmacology leading to increase the awareness of health professionals.

[Drug and food interactions with contraceptives: CNGOF Contraception Guidelines]. / Interactions avec les contraceptifs. RPC Contraception CNGOF.

INTRODUCTION: The risk of drug interaction with hormonal contraceptives should be anticipated as it may lead to unplanned pregnancies. These are frequently reported with some drugs, such as antiepileptics, and with some contraceptive methods, such as the implant, not always understood by patients as hormonal contraception. OBJECTIVES: The aim of this work was to review all drugs and foods at risk of interaction with contraceptives. METHODS: The official recommendations established by the French Agency for the safety of medicinal products have been taken into account, supported by a review of the literature. RESULTS: There is a risk of drug-drug interaction with all hormonal contraceptives regardless of their route of administration. Most interactions lead to a decrease in the effectiveness of hormonal contraceptives. If an enzyme inducer drug is started in a woman with an hormonal contraception, it is recommended, if the treatment is short, to use an additional mechanical contraception (barrier method) for the duration of the treatment and the cycle following its arrest and if the treatment is long, it is recommended to choose a non-hormonal contraceptive method. On the contrary, some drugs may increase ethinylestradiol levels and potentially the risk of complications. Exceptionally, it is the hormonal contraceptive that will alter the pharmacokinetics of another drug, for example, lamotrigine. CONCLUSIONS: The risk of drug interaction leading to a decrease in the contraceptive effectiveness needs to be known to prescribers in order to be taken into account when prescribing any new drug in a woman with hormonal contraception (and whatever its route of administration).